Sitagliptin Phosphate Monohydrate CAS 654671-77-9 Tsafta > 99.0% (HPLC) API Babban Ingancin Factory
Samar da Sitagliptin Phosphate Monohydrate Matsakaici masu alaƙa:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydrate API CAS 654671-77-9
2,4,5-Trifluorophenylacetic Acid CAS 209995-38-0
Boc-(R) -3-Amino-4- (2,4,5-Trifluoro-Phenyl) -Butyric Acid CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydrate Matsakaici CAS 486460-21-3
| Sunan Sinadari | Sitagliptin Phosphate Monohydrate |
| Makamantu | (R) -3-amino-1- (3- (trifluoromethyl) -5,6-dihydro-[1,2,4]triazolo [4,3-a] pyrazin-7 (8H) -yl)-4- (2,4,5-trifluorophenyl) butan-1-one phosphate monohydrate |
| Lambar CAS | 654671-77-9 |
| Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
| Tsarin kwayoyin halitta | Saukewa: C16H20F6N5O6P |
| Nauyin Kwayoyin Halitta | 523.3240802 |
| Matsayin narkewa | 202.0 ~ 204.0 ℃ |
| Ruwan Solubility | Mai narkewa a cikin Ruwa |
| Takamaiman Juyawa | -18.0°~-23.0° (C=1, Ruwa) |
| Alamar | Ruifu Chemical |
| Abu | Ƙayyadaddun bayanai |
| Bayyanar | Fari zuwa Kashe-White Crystalline Foda |
| Gano ta HPLC | Lokacin riƙe samfurin ya yi daidai da ma'aunin tunani |
| IR-Infrared Spectrum | IR Absorption Spectrum na samfurin zai kasance daidai da na daidaitaccen bakan |
| Phosphate | Ya bi |
| Tsarkake / Hanyar Bincike | > 99.0% (HPLC akan busasshiyar tushe) |
| Abubuwan Ruwa (KF) | 3.3% ~ 4.4% |
| Ragowa akan Ignition | ≤0.20% |
| Sulfate | ≤0.02% |
| Chloride | ≤0.05% |
| Chiral Najasa | <0.50% |
| Abubuwa masu alaƙa | |
| Tsaftace Guda Daya | <0.50% |
| Jimlar ƙazanta | <1.0% |
| Ethyl acetate | <0.50% |
| Karfe masu nauyi | <20ppm |
| Matsayin Gwaji | Matsayin Kasuwanci |
| Amfani | Matsakaicin Magunguna |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.
Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9), sabon magani don kula da nau'in ciwon sukari na 2.A watan Agustan 2009, Ƙungiyar Tarayyar Turai ta amince da maganin a matsayin magani na farko don maganin ciwon sukari na 2.Sitagliptin Phosphate shine farkon dipeptidyl peptidase-IV inhibitor da FDA ta amince da shi don amfani da shi wajen kula da nau'in ciwon sukari na 2 da nisa, ƙarƙashin sunan kasuwanci Januvia.Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) da sauri da kuma yadda ya kamata ya kaskantar da GLP-1, GLP-1, wanda shine mafi inganci stimulator na samar da insulin samar da mugunya Saboda haka, hana DPP-IV na iya haɓaka rawar GLP-1 na endogenous, ta haka ne ƙara yawan jini. matakan insulin, don haka ragewa da kiyaye matakan glucose na jini a cikin masu ciwon sukari.A halin yanzu, magani ya tabbatar da cewa mai hana DPP-IV wani sabon nau'in maganin ciwon sukari ne, kuma sakamakon asibiti ya nuna cewa magungunan suna da tasiri mai kyau na hypoglycemic.Saboda GLP-1 yana taka rawar dogaro da glucose a cikin haɓaka samar da insulin da ɓoye, halayen halayen gama gari irin su hypoglycemia da hauhawar nauyi da ke haifar da amfani da magungunan antidiabetic ba sa faruwa.
